Synagis (palivizumab) 50 mg/0.5 mL, 1 vial, AbbVie Synagis (palivizumab) is used to help prevent serious respiratory syncytial virus (RSV) lower respiratory tract disease in high-risk children. Contact +380996042415.
Delivery methods
- We can ship by mail to any European country with a delivery time of 8-10 days. Only medications that do not require refrigeration possible shipping. Shipping costs are 40-50 euro, depending on the destination country.
Delivery time
- Originator medicines: 8-10 days
- Generic medicines: 8-10 days
Payment methods
- Bank transfer to the settlement account after receiving the order
Indications of the active substances of the drug Synagis®
Prevention of severe lower respiratory tract infection caused by respiratory syncytial virus (RSV) in children at high risk of RSV infection, which include: children under 6 months of age born at 35 weeks of gestation or earlier; children under 2 years of age who have required treatment for bronchopulmonary dysplasia within the past 6 months; children under 2 years of age with hemodynamically significant congenital heart defects.
- Trade name:Synagis
- Chemical name:Palivizumab
- Dosage:50 mg
- Quantity:1
- Dosage form:Vial
No reviews yet
